If you’re on Medicare – don’t fall sick

A friend of mine pointed out some shocking data from a report released today from the Office of Inspector General.
More than a quarter of Medicare hospitalizations result in adverse events, half of them “serious” (meaning prolonged hospital stay, permanent harm, need for life sustaining intervention, death).  Strikingly, almost half these situations arise are preventable.  In other words they are the result of medical errors, sub-standard care, lack of patient monitoring and assessment and hospital acquired infections!  According to the study, these cost the taxpayer over $4 billion in 2008 (which is when the sample was taken from).
Here’s a link to the full report: http://bit.ly/recon1110a
What’s really interesting is that this contrasts with the widely publicized statistic that only 1% of hospitalized Medicare eligibles experience an adverse event per the National Quality Forum guidelines and that a similar % get hospital acquired infections per the Medicare list of such infections.  Is this a question of measuring and therefore fixing only a very narrow part of the problem.
Given CMS reaction to the report (conciliatory) we would expect them to substantially widen the definition of tracked adverse events to match the broader list used by the OIG.  And hopefully this will lead to greater focus on quality efforts by hospitals.
Share

Keep up with the Recon Strategy Insights

Get an email each time Recon takes an analytical look behind select developments in healthcare.

Suggested Articles

We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out-licensing activity than non-platforms, and accounted for nearly all multi-asset approvals within our cohort. All platform types showed increased survivability and more licensing opportunities.
Merck's acquisition of Verona is the latest in a long line of "revenue acquisitions". How have prior mid-size biopharma revenue acquisitions fared? We found that forecasts at the time of deal are often optimistic, with many transactions missing their projected sales trajectories.
The first porcine kidney transplant (in a live recipient) It’s been a year, and like many, I have been waiting for the details to be published in the NEJM (where else – especially since this was done …
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.